Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VIMPAT vs VISMODEGIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

VIMPAT vs VISMODEGIB: Safety Overview

Metric VIMPAT VISMODEGIB
Total FAERS Reports 156 8,135
Deaths Reported 20 864
Death Rate 12.8% 10.6%
Hospitalizations 57 974
Average Patient Age 46.4 yrs 69.6 yrs
% Female Patients N/A 39.3%
FDA Approval Date N/A Jan 30, 2012
Manufacturer N/A Genentech, Inc.
Route N/A ORAL
Marketing Status N/A Prescription